Laventair Ellipta

Umeclidinium bromide / vilanterol, the active ingredient in Laventair Ellipta, is a LAMA/LABA combination presented as an Ellipta inhaler for inhalation use. It provides long‑acting bronchodilation for patients with chronic obstructive pulmonary disease and asthma. GNH USA supplies Laventair Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laventair Ellipta is a bronchodilator indicated for chronic airway diseases that require long‑acting maintenance therapy. - Chronic obstructive pulmonary disease (COPD): improves lung function and reduces the frequency of exacerbations. - Asthma: provides sustained bronchodilation for maintenance treatment in adults. - COPD‑related bronchospasm: relieves airway narrowing and improves breathing.

Common Side Effects: - Cough: mild to moderate irritation of the throat. - Throat irritation: sensation of dryness or soreness. - Dry mouth: reduced salivary flow. - Headache: transient mild headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Tachycardia or arrhythmia: increased heart rate or irregular rhythm. - Hypersensitivity reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, consider the following precautions: - Assess lung function: perform spirometry to confirm diagnosis. - Monitor cardiovascular status: observe heart rate and blood pressure regularly. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Use with caution in severe hepatic impairment: increase clinical monitoring. - Store at room temperature: keep inhaler in original packaging, protect from moisture and heat.

Potential drug interactions should be reviewed prior to prescribing. Major Interactions (Avoid): - Concurrent use with other long‑acting bronchodilators: may increase cardiovascular risk. - Beta‑blockers: can diminish bronchodilator efficacy. - Strong CYP3A4 inhibitors: may raise systemic exposure of vilanterol.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypokalemia. - Theophylline: may increase plasma concentrations and side‑effect potential.